World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments

Publisher: Renub Research Published: April, 2009

Report Details
World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments published by Renub Research talks about the world vaccine market. This report gives the past, present scenario on the vaccines market and also forecast on future of vaccines market. Such as market size of Hepatitis B vaccines, Pneumococcal vaccines, Cervical Cancer vaccines etc. are there in the report. Forecast for the future market size of vaccine for diseases like Malaria, Ebola, Tuberculosis (TB), Japanese Encephalitis, West Nile, Typhoid etc. which are yet to be launched in the market have also been included in the report. The report also forecast on the sales of the key vaccines brands like Gardasil, Fluzone/Vaxigrip/Mutagrip, Prevnar, RotaTeq, Rotarix etc. Major companies vaccines sales data for the year 2007 and 2008 are also there in the report. Market Overview The vaccines landscape is very different now as compared to few years back. With increasing public awareness about preventive healthcare and increased spending by governments for the same has once again put spotlight on the vaccines. Quality of life is expected to increase markedly with introduction of newer vaccines covering more and more diseases. Due to this vaccines, which were perceived as low margin business before, have now emerged as one of the most lucrative segments in the pharmaceutical industry. Moreover with the success of a number of blockbuster products, the market place has changed dramatically. Pharma majors today look upon vaccines as a driver for their future growth. Already vaccines have become big business for pharmaceutical giants like GlaxoSmithKline, sanofi pasteur and Merck & Co.. For e.g. GSK Bio, GSK's vaccines arm, accounted for 8.4 percent of GSK's pharmaceutical turnover in 2006. And it is expected that by 2012 companies like GSK, Sanofi-aventis, Merck & Co., and Wyeth vaccines arm will fetch them more than 10 percent of sales from vaccine as a percentage of overall pharma sales. Sector wise basic pediatrics share is declining as most of the vaccines in this sector are either off patent or newer and more effective vaccines have replaced them. Proprietary pediatrics and cancer pediatrics will define the future growth going forward. Vaccines like Prevnar

Renub Research

Page 2 of 16

(Pneumococcal vaccines), Gardasil (Cervical cancer vaccines) have crossed the sales of US$ 1 Billion by 2007. In fact Prevnar became the first vaccine to cross the US$ 2 Billion annual sales in 2007. With the growth in international travel vaccine market of adult/travel sector is also going to grow further. Malaria vaccines, Typhoid Vaccines and Japanese Encephalitis Vaccines are expected to grow further in the market. Malaria vaccine which is expected to launch in 2010 or 2011, is forecasted to be worth US$ 419 Million market by 2025. Typhoid vaccine market for travelers is expected to grow with a CAGR of 4 percent from 2003 to 2014. Ongoing spate of mergers and accquisition in pharma sector its effect and causes on the overall industry. Such as Pfizer taking over Wyeth would cement Pfizers position as the worlds leading drugmaker. Geographic segment wise China and India vaccine market will grow considerably in future and Japanese vaccine market has also started to open up further from regulatory and political barriers. Overall the worldwide vaccine market has registered revenue of US$ 21 Billion in 2008. Report Forecast Worldwide Vaccine Market Influenza Market Adult/Travel Market Proprietary Pediatrics/Adolescent Market Enhanced Pediatrics Market Basic Pediatrics Market Major Vaccines Market (For complete list see heading no. 4 below in table of contents) Major Geographic Vaccine Markets Sales Forecast for Key Vaccine Brands (Cervarix, RotaTeq, Flu, Zostavax, ProQuad, Infanrix (DTP), Menactra, Rotarix, Gardasil, Prevnar, Fluzone/Vaxigrip/Mutagrip, 13Valent Pneumococcal, Synflorix, Imvamune, H5N1 Influenza Vaccine, Hepatitis B vaccine).

Renub Research

Page 3 of 16

Research Highlights M&A by big pharma like Pfizer and Merck and its effect in terms of consolidation in pharma industry. Collectively Europe & Asia Pacific accounts for the 60 percent of the Hepatitis B vaccine market. Public market share of malaria vaccine revenue increases from 43 percent in 2015 to 77 percent in 2025. Japanese encephalitis vaccine market is expected to cross the figure of US$ 400 Million by 2012. By 2015 it is expected that Cervical Cancer patients will be 320 Thousand worldwide. India and China vaccine market is expected to grow with a CAGR of 16 and 17.8 percent respectively from 2006 to 2013. Vaccines like Infanrix (DTP) of GSK and Flu vaccine of sanofi pasteur will have a market of more than US$ 1 Billion by 2010. Despite global slowdown vaccine sale of all major companies such as Merck, GSK, Sanofi Aventis has been increased in 2008 compared to 2007. 14 different vaccines have been analyzed in the report (for details refer heading no. 4 below in table of contents). Data Sources The information and data in this report has been collected from various printable and nonpintable sources like Magazines, Newspapers, Trade Journals, White papers, Online paid databases, News websites Government Agencies and Trade associations.

Renub Research

Page 4 of 16

Published By Renub Research A116B, Sector27 Noida 201301 Phone: +91-120-421-9822, 254-5750 (India) +1-678-302-0700 (USA) Fax : +91-120-424-9780 Email: info@renub.com www.renub.com

World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments Renub Research, 2009 Edition 1.0 All rights reserved. This publication is protected by copyright. No part of it may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic mechanical, photocopying, recording or otherwise without the prior written permission of the publishers

Renub Research

Page 5 of 16

Table of Contents
1. 2. Executive Summary Vaccines Market - Why is it so Attractive

2.1 2.2 2.3

3.

Big Pharma Upping Their Commitment to Vaccines Vaccine 'Outsiders' Jumping Onto Bandwagon (Acquisitions by Big Pharma Players) Several New Vaccines, Many with Blockbuster Potential By Sector Vaccine Market Influenza Adult/Travel Proprietary Pediatrics/Adolescent Enhanced Pediatrics Basic Pediatrics

Worldwide Vaccine Market

3.1

3.1.1 3.1.2 3.1.3 3.1.4 3.1.5

4.

Major Vaccine Cases, Market Sizes & Future Forecast

4.1 4.2

Pneumococcal Vaccines Market Size of Pneumococcal Vaccines & Future Forecast Number of Polio Cases (in 42 Countries) Market Size of Polio Vaccines & Future Forecast Number of Meningitis Cases Market Size of Meningitis Vaccines & Future Forecast Number of Rotavirus Cases (in 27 Countries) Market Size of Rotavirus Vaccines & Future Forecast Number of Tuberculosis Cases Market Size of Tuberculosis Vaccines & Future Forecast Number of Measles, Mumps & Rubella Cases Number of Diphtheria, Pertussis and Tetanus Cases Polio Vaccines

4.1.1 4.2.1 4.2.2 4.3 4.3.1 4.3.2 4.4 4.4.1 4.4.2 4.5 4.5.1 4.5.2 4.6 4.7 4.6.1 4.7.1

Meningitis Vaccines

Rotavirus Vaccines

Tuberculosis (TB) Vaccines

Measles, Mumps & Rubella (MMR) Vaccines DTP Vaccines

Renub Research

Page 6 of 16

4.7.2 4.8 4.8.1 4.8.2 4.9 4.9.1 4.9.2 4.10 4.10.1 4.10.2 4.11 4.11.1 4.11.2 4.12 4.12.1 4.12.2 4.13 4.13.1 4.13.2 4.14 4.14.1 4.14.2
5.

Market Size of DTP Vaccines Percent of Hepatitis B Vaccine Immunization Market Size of Hepatitis B Vaccines & Future Forecast Number of Malaria Cases Market Size of Malaria Vaccines Market Future Forecast Number of Japanese Encephalitis Cases Market Size of Japanese Encephalitis Vaccines & Future Forecast Number of West Nile Cases Market Size of West Nile Vaccines & Future Forecast Number of Ebola Cases Market Size of Ebola Vaccines & Future Forecast Number of Cancer & Cervical Cancer Cases Market Size of Cervical Cancer Vaccines & Future Forecast Number of Typhoid Cases Market Size of Typhoid Vaccines & Future Forecast

Hepatitis B Vaccines

Malaria Vaccines

Japanese Encephalitis Vaccines

West Nile Vaccines

Ebola Vaccines

Cervical Cancer Vaccines

Typhoid Vaccines

Major Geographic Markets

5.1 5.2 5.3 5.4

6.

India Vaccine Market China Vaccine Market Japan Vaccine Market US Vaccine Market Worldwide 5 Major Companies Forecast of Vaccine Sales as Percentage of Overall Worldwide Sales Forecast for Key Vaccine Brands Global Economic Crisis - Increase in Vaccine Sales

Competitive Landscape

6.1 6.2 6.3

Pharma Sales

Renub Research

Page 7 of 16

List of Figures:
Figure 2-1: Worldwide Vaccines: GSK, Merck & Co., Novartis & Sanofi-aventis - Sales as a Percentage of Overall Pharma Sales (in Percent), 2006 Figure 3-1: Worldwide Vaccine Market (in Billion US$), 2007 - 2013 Figure 3-2: Worldwide Influenza Vaccine Market (in Million US$), 2004 2008 Figure 3-3: Worldwide Forecast for Influenza Vaccine Market (in Million US$), 2009 2013 Figure 3-4: Worldwide Adult/Travel Vaccine Market (in Million US$), 2004 2008 Figure 3-5: Worldwide Forecast for Adult/Travel Vaccine Market (in Million US$), 2009 2013 Figure 3-6: Worldwide - Proprietary Pediatrics/Adolescent Vaccine Market (in Million US$), 2004 2008 Figure 3-7: Worldwide - Forecast for Proprietary Pediatrics/Adolescent Vaccine Market (in Million US$), 2009 2013 Figure 3-8: Worldwide - Enhanced Pediatrics Vaccine Market (in Million US$), 2004 2008 Figure 3-9: Worldwide - Forecast for Enhanced Pediatrics Vaccine Market (in Million US$), 2009 2013 Figure 3-10: Worldwide - Basic Pediatrics Vaccine Market (in Million US$), 2004 2008 Figure 3-11: Worldwide - Forecast for Basic Pediatrics Vaccine Market (in Million US$), 2009 2013 Figure 4-1: Worldwide - Pneumococcal Vaccine Pipeline Figure 4-2: Worldwide - Pneumococcal Vaccine Market (in Billion US$), 2004 - 2007 & 2018F Figure 4-3: Worldwide Forecast for Global Funds for Immunization in Pneumococcal Vaccine Market (in Billion US$ & Percent), 2018 Figure 4-4: Worldwide - Number of Polio Virus Cases, 2000 March 2009 Figure 4-5: Worldwide - Polio Vaccine Market (in Million US$), 2004 & 2011F Figure 4-6: Africa Number of Meningitis Cases (in Number), 2001 2007 Figure 4-7: Worldwide - Meningitis Vaccine Market (in Billion US$), 2004 & 2010F Figure 4-8: Worldwide - Forecast for Rotavirus Vaccine Market (in Billion US$), 2010 Figure 4-9: Worldwide By Geographic Region Number of Tuberculosis Cases (in Thousand), 2006 Figure 4-10: Worldwide Distribution of Tuberculosis Patients in Previous Cases, New Smear-positive Cases & HIV-positive Cases (in Million & Percent), 2006 Figure 4-11: Worldwide Forecast for TB BCG-Replacement Vaccine (in US$ Million), 2013 2030 Figure 4-12: Worldwide Forecast for TB Booster Vaccine (in US$ Million), 2013 -2030 Figure 4-13: Worldwide Forecast for TB Prime-Boost Strategy (in US$ Million), 2013 2030 Figure 4-14: Worldwide By Player Share of DTP Combos Market (in Million & Percent), 2004 Figure 4-15: Worldwide By Region Hepatitis B Vaccine Immunization Coverage (in Percent), 2007 Figure 4-16: Worldwide - Hepatitis B Vaccine Market (in Billion US$), 2005 - 2010F Figure 4-17: Worldwide Combined Hepatitis B Vaccine Market of Europe & Asia Pacific Region (in Billion & Percent US$), 2006 Figure 4-18: Worldwide Forecast for Malaria Vaccine Market (in Million US$), 2010 2025

Renub Research

Page 8 of 16

Figure 4-19: Worldwide Forecast for Military Market for Malaria Vaccine (in Million US$), 2010 2025 Figure 4-20: Worldwide Forecast for Private Market for Malaria Vaccine (in Million US$), 2010 2025 Figure 4-21: Worldwide Forecast for Public Market for Malaria Vaccine (in Million US$), 2010 2025 Figure 4-22: Worldwide - Japanese Encephalitis Vaccine Market (in Million US$), 2004 2007 Figure 4-23: Worldwide Forecast for Japanese Encephalitis Vaccine Market (in Million US$), 2008 2012 Figure 4-24: Worldwide Japanese Encephalitis Vaccine Market Growth (in Percent), 2004 2012F Figure 4-25: US Number of West Nile Virus Cases & Deaths (in Numbers), Since 1999 Figure 4-26: Worldwide Forecast for West Nile Vaccines Market (in Million US$), 2010 Figure 4-27: Worldwide Number of Ebola Cases & Deaths (in Numbers) Figure 4-28: Worldwide & US Forecast of Ebola Vaccines Market (in Million US$), 2011 Figure 4-29: Worldwide Forecast for Cervical Cancer Cases (in Numbers), 2015 & 2030 Figure 4-30: Worldwide - Cervical Cancer Vaccines Market (in Billion US$), 2007 2010F Figure 4-31: Worldwide - Number of Typhoid Cases (in Numbers) Every Year Figure 4-32: Worldwide Travelers Market for Typhoid Vaccine (in Million US$), 2003 & 2014F Figure 5-1: India Vaccine Market (in Million US$), 2006 2013F Figure 5-2: India Share of Pediatric Vaccine Market & Adult/Travel & Therapeutic Market (in Million US$ & Percent), 2006-07 Figure 5-3: China Vaccine Market (in Million US$), 2006 2013F Figure 5-4: China Market Share of Chinese & Foreigner Drug Manufacturer in Vaccine (in US$ Million & Percent), 2006 Figure 5-5: Japan Vaccine Market (in Million US$), 2008 & 2016F Figure 5-6: US Vaccine Market (in Billion US$), 2003 & 2008E

Renub Research

Page 9 of 16

List of Tables:
Table 2-1: Worldwide 15 Major Acquisitions in Pharmaceuticals (in Billion US$), 2005 2009 Table 2-2: Worldwide 16 Major Acquisitions in Biotechnology (in Billion US$), 2005 2009 Table 2-3: Worldwide Vaccines Market: Prevnar, Gardasil, Engerix-B, Havrix, Twinrix, Infanrix, Pediarix, Fluzone, and IPOL, Hib, Petrussis Sales (in Billion US$), 2006 - 2008 Table 4-1: Worldwide Top 42 Countries with Maximum Number of Polio Cases, 2000 March 2009 Table 4-2: Worldwide 27 Countries with Number of Diarrhea Hospitalizations Cases and Rotavirus Cases (in Number & Percent), 20002004 Table 4-3: Worldwide By Geographic Region Number of Measles Cases, 2000 - 2007 Table 4-4: Worldwide By Geographic Region Number of Mumps Cases, 2000 2007 Table 4-5: Worldwide By Geographic Region Number of Rubella Cases, 2000 2007 Table 4-6: Worldwide By Geographic Region Number of Diphtheria Cases, 2000 2007 Table 4-7: Worldwide By Geographic Region Number of Pertussis Cases, 2000 2007 Table 4-8: Worldwide By Geographic Region Number of Tetanus Cases, 2000 2007 Table 4-9: Worldwide By Geographic Region Number of Malaria Cases, 2004 2006 Table 4-10: Worldwide By Geographic Region Number of Japanese Encephalitis Cases, 2006 & 2007 Table 4-11: Worldwide By Geographic Region Estimated Cancer Patients (in Numbers), 2007 Table 5-1: China - Vaccine Classification Table 6-1: Worldwide Forecast for Vaccines: GSK, Merck & Co., Novartis, Sanofi-aventis & Wyeth Sales as a Percentage of Overall Pharma Sales (in Percent), 2009 2012 Table 6-2: Worldwide Sales Forecast for Vaccines Market: Cervarix, RotaTeq, Flu, Zostavax, ProQuad, Infanrix (DTP), Menactra, Rotarix (in Million US$), 2010 Table 6-3: Worldwide Revenues of Vaccine Brands: Gardasil, Prevnar, Fluzone/Vaxigrip/Mutagrip, RotaTeq (in Million US$) 2007 & 2012F Table 6-4: Worldwide Revenue Forecast of Vaccine Brands: 13-Valent Pneumococcal, Synflorix, Imvamune, H5N1 Influenza Vaccine, Hepatitis B vaccine (in Million US$), 2012 Table 6-5: Worldwide Vaccine Sales of Companies: Merck, GSK, Sanofi Aventis, Wyeth, Novartis, Sanofi Merck Pasteur, Baxter, Crucell, Saloy Mitsubishi-Tanable (in US$ Billion), 2007 & 2008

Renub Research

Page 10 of 16

Order Form
Scan and e-mail this page to info@renub.com, alternatively one can also write the Contact Information in an e-mail and mail it. Else you can also fax this form to +91-120-424-9780 Questions? Please call +91-120-421-9822 (India), +1-678-302-0700 (USA) or mail to info@renub.com

Format
Report Title: World Vaccines Market 2008-2013: Future Forecast, Critical Trends and Developments Single User (Email from Publisher) US$ 800 Hard Copy (Mail Delivery) US$ 800 CD Rom (Mail Delivery) US$ 800 Global Site License (Multiple User License) US$ 900

For ordering this report: Three easy ways to place your order:
1) Order online by Credit Card (Visa, MasterCard, etc.): http://renub.com/reports/showdetails.aspx?id=13 2) Order by Wire Transfer: http://renub.com/reports/wiretransfer.aspx?id=13&pid=1048 To pay by Wire Transfer, please, fill in your contact details in the form below:

Renub Research

Page 11 of 16

Bank Details
Account Name: Renub Research A/C No.: 109102000023296 Name of Bank: IDBI Bank Ltd. Swift Code: IBKLINBB010 Bank Address: 4th Floor Indian Red Cross Building 1 Red Cross Road Opposite Parliament Street New Delhi 110001 India

Contact Information
First Name: Email: Job Title: Company: Address: City: Postal/Zip Code: Country: Phone: Mobile: Fax: Report Format: Your message: Last Name:

Renub Research

Page 12 of 16

3) Order by Check Please post the check accompanied by this form, to: Company Address: Renub Research A -116B Sector -27 Noida - 201301 Uttar Pradesh India Phone: +91-120-421-9822, 424-9780

For free Sample copy report or to view any of our sample work please contact us at info@renub.com or call +91-120-421-9822 (India), +1-678-302-0700 (USA)

Follow Us
Facebook: http://www.facebook.com/pages/Renub-Research/233380966701090 LinkedIn: http://www.linkedin.com/company/renub-research Twitter: http://twitter.com/RenubResearch

Renub Research

Page 13 of 16

Our Partial List of Clients

Redbus Becton Dickinson Pfizer Intercell Sanofi Pasteur Stanford Burgess Pequot Capital DMI Transgene S.A. ixia communications Toyota Tsusho Amercia Inc. National Health Research Institutes Abbott Diabetes Care Corning Incorporated - Life Sciences L.E.K. Consulting GmbH Syntiron MediVas LLC Credit Suisse Dune Medical QIAGEN Inje University Mapp Biopharmaceutical Institute for Information Industry NorDiag ASA Rep e Inv Medicas SA de Innogenetics

Bain WAKE Technology Services, Inc. PSS World Medical Relypsa C&K components Konkuk University Resonetics Samsung SEKISUI MEDICAL CO. LTD. Plentyoffish Media INC Arthur D Little Gmbh Morgan Stanley Takeda Pharmaceutical Corporation Hokkai School of Commerce Ministry of Manpower Singapore GenOmind, LLC. Goldman Sachs & Co NTT Advanced Technology Tokyo Womens Medical University The Chemo-Sero-Therapeutic Research Trade Council of Iceland Jpmorgan, Ets Trading GE Healthcare IT ixia communications

Renub Research

Page 14 of 16

Disclaimer
Most of the information available in this report is within the public domain. The submitting authors or other copyright holders retain rights for reproduction or redistribution. All persons reproducing or redistributing this information are expected to adhere to the terms and constraints invoked by the copyright holder. Such protected material, however, may be used under the terms of "fair use as defined in the copyright laws, which generally permit use for non-commercial educational purposes such as teaching, research, criticism, and news reporting. With respect to documents available, neither the company nor any of its employees makes any warranty, express or implied, including the warranties of merchantability and fitness for a particular purpose, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Unless otherwise stated, the copyright, database rights, and similar rights in all material published on this manual is solely owned by Renub Research. You are permitted to print or download extracts from this material for your personal use only. None of this material may be used for any commercial or public use. No part of this manual or any material appearing may be reproduced, stored in or transmitted on any other Web site without written permission of www.renub.com and any payments of a specified fee. Requests to republish any material may be sent to us at info@renub.com.

Renub Research

Page 15 of 16

About Us
Renub Research is a leading Market Research and Information Analysis Company with centers at Noida India and Roswell USA. We have more than 7 years of experience especially in international Business-to-Business Researches, Surveys, Business and Consulting. Throughout the years we have acquired expertise in most market sectors, including Information Technology (IT), Telecoms, Life Sciences, Medical & Pharmaceuticals, Financial Services (Banking, Insurance, Reinsurance, M&A, etc.), Energy, Chemicals, Automotive, Retail, FMCG, Consumer Goods, Logistics, Governmental, Social, and Others. Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. We support many blue chip companies by providing them findings and perspectives across a wide range of markets. Our research reports offer a blend of information insight, analysis and forecasting that is essential in todays ultra-competitive markets.

Renub Research

Page 16 of 16